BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 19097715)

  • 1. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
    Valiati B; Capp E; Edelweiss MI; de Freitas FM; Wender MC
    Maturitas; 2009 Jan; 62(1):81-4. PubMed ID: 19097715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
    Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
    Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
    Palacios S; Farias ML; Luebbert H; Gomez G; Yabur JA; Quail DC; Turbi C; Kayath MJ; Almeida MJ; Mönnig E; Nickelsen T
    Am J Obstet Gynecol; 2004 Jul; 191(1):121-31. PubMed ID: 15295352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
    Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women.
    Archer DF;
    Menopause; 2003; 10(6):516-21. PubMed ID: 14627859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
    Schaefers M; Muysers C; Alexandersen P; Christiansen C
    Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
    Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ
    Menopause; 1999; 6(3):188-95. PubMed ID: 10486787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
    O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
    Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study.
    D'Anna R; Cannata ML; Atteritano M; Cancellieri F; Corrado F; Baviera G; Triolo O; Antico F; Gaudio A; Frisina N; Bitto A; Polito F; Minutoli L; Altavilla D; Marini H; Squadrito F
    Menopause; 2007; 14(4):648-55. PubMed ID: 17251874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses.
    Carranza-Lira S; Gooch AL; Saldivar N; Osterwalder MS
    Int J Fertil Womens Med; 2007; 52(2-3):93-6. PubMed ID: 18320867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies.
    Rogers A; Clowes JA; Pereda CA; Eastell R
    Bone; 2007 Jan; 40(1):105-10. PubMed ID: 16934544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study.
    Nahas EA; Nahas-Neto J; Orsatti FL; Carvalho EP; Oliveira ML; Dias R
    Maturitas; 2007 Nov; 58(3):249-58. PubMed ID: 17913408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial.
    Haines C; Yu SL; Hiemeyer F; Schaefers M
    Climacteric; 2009 Oct; 12(5):419-26. PubMed ID: 19479489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study.
    D'Anna R; Cannata ML; Marini H; Atteritano M; Cancellieri F; Corrado F; Triolo O; Rizzo P; Russo S; Gaudio A; Frisina N; Bitto A; Polito F; Minutoli L; Altavilla D; Adamo EB; Squadrito F
    Menopause; 2009; 16(2):301-6. PubMed ID: 19034051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial.
    Honjo H; Taketani Y
    Climacteric; 2009 Aug; 12(4):319-28. PubMed ID: 19330598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
    Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
    Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
    Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.